ABVC BioPharma, Inc.
ABVC
$2.41
-$0.12-4.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 104.47% | -- | -- | -91.08% | 2,348.43% |
| Total Other Revenue | -- | -- | -- | 92.28% | -41.51% |
| Total Revenue | 104.47% | -- | -- | -9.09% | 2,348.43% |
| Cost of Revenue | -- | -- | -- | -100.00% | -98.99% |
| Gross Profit | 104.63% | -- | -- | 101.46% | 2,939.42% |
| SG&A Expenses | 196.02% | 141.45% | -76.03% | 0.50% | -67.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -130.99% | -- | -- | 3,891.67% | -34.26% |
| Total Operating Expenses | 180.84% | 134.85% | -75.59% | -25.57% | -67.97% |
| Operating Income | -276.80% | -166.83% | 75.58% | 25.65% | 85.71% |
| Income Before Tax | -164.22% | -99.36% | 67.75% | 124.55% | 85.54% |
| Income Tax Expenses | 25.00% | 121.28% | -- | -100.00% | 140.00% |
| Earnings from Continuing Operations | -164.16% | -122.72% | 67.75% | 118.41% | 85.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -55.77% | -27.88% | 9.20% | -68.33% | 83.20% |
| Net Income | -215.73% | -139.52% | 70.29% | 159.82% | 88.10% |
| EBIT | -276.80% | -166.83% | 75.58% | 25.65% | 85.71% |
| EBITDA | -283.73% | -170.23% | 75.82% | 26.60% | 85.99% |
| EPS Basic | -68.55% | -56.01% | 80.66% | 130.31% | 96.11% |
| Normalized Basic EPS | -129.20% | -53.08% | 82.89% | -7.33% | 97.30% |
| EPS Diluted | -68.55% | -56.01% | 80.66% | 129.59% | 96.12% |
| Normalized Diluted EPS | -129.20% | -53.08% | 82.89% | -7.33% | 97.30% |
| Average Basic Shares Outstanding | 87.47% | 53.57% | 53.74% | 97.77% | 205.90% |
| Average Diluted Shares Outstanding | 87.47% | 53.57% | 53.74% | 97.77% | 205.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |